Day: August 7, 2020

MONTRÉAL, 06 août 2020 (GLOBE NEWSWIRE) — Groupe Vision New Look Inc. (« Vision New Look » ou la « société ») (TSX: BCI), un chef de file dans la vente au détail dans l’industrie de l’optique au Canada avec ses magasins au Canada et en Floride, a annoncé aujourd’hui ses résultats financiers pour les périodes de 13 et de 26 semaines terminées le 27 juin 2020 (deuxième trimestre de 2020) et a fait le point sur les mesures qu’elle a prises en réaction à la COVID-19, les réouvertures de magasins et les nouveaux arrangements financiers. Ce communiqué doit être lu à la lumière du rapport de gestion et des états financiers consolidés intermédiaires pour le deuxième trimestre de 2020, qui sont disponibles sur le site de la société à l’adresse www.newlookvision.ca/Investisseurs et également sur SEDAR à l’adresse www.sedar.com.  Faits saillants...

TOKYO, Aug. 07, 2020 (GLOBE NEWSWIRE) — Internet Initiative Japan Inc. (“IIJ”, TSE1: 3774) today announced its consolidated financial results for the first three months for the fiscal year ending March 31, 2021 (“1Q20”, from April 1, 2020 to June 30, 2020) under International Financial Reporting Standards (IFRS).1Overview of 1Q20 Financial Results and Business Outlook“We started FY2020 with well-accomplished first quarter: accumulation of enterprise network services as well as profit improvement significantly exceeded our expectation. Amid the abnormal circumstance caused by the COVID-19, we were able to continuously and structurally improve operating profit by following FY2019 trend of solid accumulation of enterprise network services, which are all monthly recurring revenues. The COVID-19 has absolutely stimulated slow-moving...

HOUSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) — Houston Wire & Cable Company (NASDAQ: HWCC) (the “Company”) announced operating results for the second quarter ended June 30, 2020 and progress on its cost and debt reduction programs.Revenue of $66.8 millionGAAP net loss of $2.2 million after a $0.2 million non-cash tradename impairment charge, compared to net income of $1.6 million in the second quarter of 2019Operational UpdatePresident & Chief Executive Officer James Pokluda commented “Although the Board and the Company acted quickly to reduce cost and debt, execute plans to provide a safe working environment, assure business continuity and operational excellence and reduce costs, the rapid and pervasive economic downturn resulting from the COVID-19 pandemic negatively impacted the Company’s financial performance during the...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) — FIREWEED ZINC LTD. (“Fireweed” or the “Company”) (TSXV: FWZ) is pleased to announce closing of the non-brokered private placement (the “Offering”) announced July 15, 2020 for total gross proceeds of CAD$5.2 million. Highlights$5.2 million Offering over-subscribedInsiders, namely Directors, Management, and their proxies, participated for a total of 521,697 Units plus 76,961 Flow Through Shares in the financing to add to their holdingsFinancing will provide Fireweed with capital to fund the 2020 work program primarily focused on drilling in the Boundary Zone at Macmillan Pass but also exploration of new target areasFireweed CEO Brandon Macdonald stated, “Thanks to impressive...

CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share. All of the shares are being offered by Checkmate. Checkmate’s common stock is expected to begin trading on the Nasdaq Global Market under the ticker symbol “CMPI” on August 7, 2020. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Checkmate, are expected to be approximately $75,000,000. The offering is expected to close on August 11, 2020, subject to the satisfaction of...

ROAD TOWN, British Virgin Islands, Aug. 06, 2020 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA) (B3: AURA32) (the “Company” or “Aura”) today announces the settlement of the Over-Allotment BDRs (as defined below) of the previously announced initial primary and secondary public offering with restricted efforts of Brazilian depositary receipts (certificados de depósito de ações, or “BDRs“), sponsored level II, issued by Itaú Unibanco S.A., as depositary institution, with each BDR representing one share of the Company (each, a “Share”) (the “Offering”).The Offering consisted of (i) a primary public offering with restricted efforts of, initially, 331,033 BDRs (the “Primary Offering” and the “Primary Offering BDRs”), representing 331,033 Shares, and a secondary public offering with restricted efforts of, initially,...

HAMILTON, Bermuda, Aug. 06, 2020 (GLOBE NEWSWIRE) — Sirius International Insurance Group, Ltd. (Nasdaq: SG) (“Sirius Group”, the “Company”, or the “Group”) today reported results for the second quarter ended June 30, 2020. The Company reported comprehensive income of $50 million for the second quarter of 2020 compared to comprehensive income of $8 million for the second quarter of 2019. For the six months ended June 30, 2020, the comprehensive loss was $(135) million compared to comprehensive income of $84 million for the six months ended June 30, 2019. The Group recorded a combined ratio of 96% for the quarter ended June 30, 2020.Book value per common share was $13.18 as of June 30, 2020 compared to $12.78 as of March 31, 2020 and $14.23 as of December 31, 2019, an increase of 3.1% for the quarter and a decrease of 7.4% for the...

EBITDA1 of $43 million on Sales of $397 million Net Debt to Invested Capital1 of 22%; Liquidity of $497 millionChief Financial Officer AppointmentVANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) — INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX: IFP) Interfor recorded net earnings in Q2’20 of $3.2 million, or $0.05 per share, compared to $6.3 million, or $0.09 per share in Q1’20 and a net loss of $11.2 million, or $0.17 per share in Q2’19.  Adjusted net earnings were $10.6 million in Q2’20 compared to $0.7 million in Q1’20 and an Adjusted net loss of $16.2 million in Q2’19.Adjusted EBITDA was $42.8 million on sales of $396.8 million in Q2’20 versus $36.6 million on sales of $479.6 million in Q1’20.Notable items in the quarter included:•  Strengthened Financial PositionNet debt ended the quarter at $239.1 million,...

ACHESON, Alberta, Aug. 06, 2020 (GLOBE NEWSWIRE) — ENTREC Corporation (“ENTREC” or the “Company”) has announced that it has obtained an extension of the stay period previously granted in an order from the Court of Queen’s Bench of Alberta (the “Court”) in support of its restructuring efforts under the Companies’ Creditors Arrangement Act (the “CCAA”). On May 15, 2020, ENTREC obtained an initial order (the “Initial Order”) from the Court commencing proceedings under the CCAA.  Pursuant to the Initial Order, among other things, a stay of proceedings was granted in respect of the Company and its subsidiaries to allow them to continue to operate their business without disruption while ENTREC pursues potential strategic and restructuring alternatives, which may include a sale, investment or other restructuring transaction under Court supervision...

BRIDGEWATER, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 second quarter financial results on Tuesday, August 11, 2020, after the close of the U.S. financial markets.Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:  About Osmotica Pharmaceuticals plcOsmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of four promoted products and approximately 30...